Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS-SC formulary step therapy Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Formulary step therapy and prior authorization rules for selected drugs

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists step therapy and prior authorization criteria for specific formulary products and applies to Blue Cross Blue Shield - South Carolina members and providers managing these drugs.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization rules for selected drugs
    Policy CodePolicy N/A
    Change TypeMinor / index update (no material change)
    Effective DateApr 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionDocument trials of required prior therapies (e.g., topical fluorouracil or imiquimod before Diclofenac Sodium GEL 3%).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleproducts listed with criteria
    04/01/2026effective date
    11version
    Diclofenacmost prominently listed drug

    Coverage Criteria

    Diclofenac Sodium GEL 3% Initial Therapy

    Covered when ALL of the following are met:

    Diclofenac Sodium GEL 3% criteria: Trial of either topical fluorouracil or topical imiquimod

    Formulary ID: 26216, Version: 11

    Antidepressants Initial Therapy

    Covered when ALL of the following are met:

    Antidepressant trial requirement: Trial of two generics from the specified list: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    Atypical Antipsychotics Initial Therapy

    Covered when ALL of the following are met:

    Atypical antipsychotic trial requirement: Trial of two oral generic formulary atypical antipsychotic agents from: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    Invega Hafyera Initial Therapy

    Covered when ALL of the following are met:

    Invega Hafyera trial requirement: Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    Relistor Initial Therapy

    Covered when ALL of the following are met:

    Relistor trial requirement: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose

    Formulary ID: 26216, Version: 11

    Rytary Initial Therapy

    Covered when ALL of the following are met:

    Rytary trial requirement: Trial of one generic carbidopa/levodopa containing formulation

    Formulary ID: 26216, Version: 11

    Zonisade Initial Therapy

    Covered when ALL of the following are met:

    Zonisade trial requirement: Trial of generic zonisamide capsule. Step applies to new starts only. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    This section is an index/listing of drug names and related entries and does not contain coverage criteria or specific exclusions. Use the index entries to locate the individual drug policy pages for detailed coverage rules, prior authorization, step therapy, and documentation requirements.

    The content shown here is an index only and does not include any medical necessity, coverage, or exclusion criteria. Refer to the referenced policy pages (by drug name and page number) for the specific coverage rules and requirements.

    This fragment is an index listing (drug names and titration pack entries) and does not present coverage rules, clinical criteria, or exclusion statements. Consult the full policy pages for each listed product to find applicable coverage criteria.

    The section shown is an index of drugs and titration packs and does not provide coverage criteria or exclusions. Use the index references to navigate to the individual drug policies where coverage rules and authorization details are specified.

    Not applicable in terms of coverage criteria — this portion is index material only. It lists drugs and score references but contains no medical necessity or exclusion language.

    This index fragment does not include coverage statements or exclusion rules. It serves solely as a table-of-contents style listing to locate detailed policy content elsewhere in the document.

    Provider Actions & Prior Authorization

    Prior Authorization

    Prior authorization requires trial of topical fluorouracil or imiquimod

    Trial of either topical fluorouracil or topical imiquimod is required before prior authorization will be granted for Diclofenac Sodium GEL 3%.

    • Required trial: topical fluorouracil OR topical imiquimod
    Prior Authorization

    Prior authorization: trial of two generics required (continuation approved)

    For listed antidepressant products, prior authorization for new starts requires documentation of trials of two generic agents from the specified list; continuation of prior therapy is approved.

    • Required trial: two generics from bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride
    • Continuation of prior therapy is approved

    Initial Therapy Criteria

    Diclofenac Sodium GEL 3% Initial Therapy

    Diclofenac Sodium GEL 3% initial therapy — single top-level criterion:

    Diclofenac Sodium GEL 3% criterion: Trial of either topical fluorouracil or topical imiquimod

    Formulary ID: 26216, Version: 11

    Antidepressants Initial Therapy

    Antidepressants initial therapy — single top-level criterion:

    Antidepressant criterion: Trial of two generics from the specified list: bupropion; mirtazapine; citalopram (tablet or solution); desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    Atypical Antipsychotics Initial Therapy

    Continuation of Therapy

    Continuation Therapy

    Continuation of prior therapy is generally approved for the listed products when the member is already receiving the therapy.

    Continuation allowed: Approve for continuation of prior therapy where specified (antidepressants, atypical antipsychotics, Invega Hafyera, Zonisade).

    Formulary ID: 26216, Version: 11

    Step Therapy Rules

    ProductStep requirement (new starts only)Continuation of prior therapy
    Invega HafyeraTrial of one of the following: Invega Sustenna or Invega Trinza. (Step applies to new starts only)Approve for continuation of prior therapy.
    ZonisadeTrial of generic zonisamide capsule. (Step applies to new starts only)Approve for continuation of prior therapy.

    Background

    This extract is an index/table of contents fragment listing drug names and titration packs. It does not provide clinical background, coverage criteria, or guidance — consult the individual drug policy pages for clinical context and authorization requirements.

    Definitions & Index Entries

    Index of Drugs
    TermIndex of Drugs
    MeaningListing of drug names and where to find their policy pages or score entries within the document (index/table of contents).
    Example entryDiclofenac Sodium ................................................ 1, Actinic Keratosis - Score 1
    Index Of Drugs
    TermIndex Of Drugs
    PurposeRepeated index pages that list drug names and cross-reference page or score locations for the policy document.
    Common items
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization rules for selected drugs
    Policy CodePolicy N/A
    Change TypeMinor / index update (no material change)
    Effective DateApr 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionDocument trials of required prior therapies (e.g., topical fluorouracil or imiquimod before Diclofenac Sodium GEL 3%).
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions & Prior AuthorizationInitial Therapy CriteriaContinuation of TherapyStep Therapy RulesBackgroundDefinitions & Index Entries
    Prior Authorization

    Prior authorization: trial of two generic atypical antipsychotics required

    Prior authorization for Fanapt and related titration packs requires documentation of trials of two oral generic formulary atypical antipsychotic agents from the listed agents; continuation of prior therapy is approved.

    • Required trial: two oral generic atypical antipsychotics from asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
    • Continuation of prior therapy is approved
    Prior Authorization

    Prior authorization: trial of Invega Sustenna or Trinza required for new starts

    For new starts of Invega Hafyera, prior authorization requires a trial of Invega Sustenna or Invega Trinza; members already receiving Invega Hafyera may be approved for continuation of prior therapy.

    • Required trial for new starts: Invega Sustenna OR Invega Trinza
    • Step applies to new starts only; continuation is approved
    Prior Authorization

    Prior authorization: trial of specified laxatives required

    Prior authorization for Relistor requires documentation of a trial of one of the listed laxatives before approval will be granted.

    • Required trial: lubiprostone, Constulose, Enulose, Generlac, OR lactulose
    Prior Authorization

    Prior authorization: trial of generic carbidopa/levodopa required

    Prior authorization for Rytary requires documentation of a trial of a generic carbidopa/levodopa containing formulation prior to approval.

    • Required trial: one generic carbidopa/levodopa containing formulation
    Prior Authorization

    Prior authorization: trial of generic zonisamide capsule required for new starts

    For new starts of Zonisade, prior authorization requires a documented trial of a generic zonisamide capsule; members already receiving therapy may be approved for continuation.

    • Required trial for new starts: generic zonisamide capsule
    • Step applies to new starts only; continuation is approved
    Note

    Index section — no prior authorization requirements listed

    These index pages list drugs and topics but do not state prior authorization requirements; use the individual drug policy pages for authorization details.

    • Index lists drug names and score/page references only
    • No prior authorization information provided here
    Note

    Index — no prior authorization information

    This index fragment is a listing of drugs and does not specify any prior authorization requirements.

    • Index-only content; no PA rules
    Note

    Index: refer to individual drug policy pages for prior authorization

    The index does not specify prior authorization requirements; refer to the individual drug policy pages indicated by the index references for authorization rules.

    • Index entries point to drug policy pages for PA details
    Note

    Prior authorization not specified in this index fragment

    This index fragment does not state prior authorization requirements and contains only listing content.

    • No PA instructions on this index page
    Note

    Index — prior authorization not specified

    This index section lists drugs but does not specify any prior authorization requirements.

    • Index-only content; no PA details provided
    Note

    Prior authorization not specified in index (none listed)

    No prior authorization requirements are specified in this index section; it is an index/listing only.

    • Index entries only; consult drug pages for PA rules
    Note

    Index — no prior authorization info

    This index fragment is an index only and does not state prior authorization requirements.

    • Index-only fragment; no authorization guidance
    Note

    Index — no PA stated

    This index section is a listing only and does not state any prior authorization requirements.

    • Index-only; no PA requirements included
    Note

    Prior Authorization (none specified in this index fragment)

    No prior authorization requirements are specified in this index fragment; it contains listing content only.

    • Consult individual drug pages for PA rules
    Note

    Index — no PA details

    These index pages list drug names and page references but do not provide prior authorization details; consult the indicated policy pages for authorization instructions.

    • Index entries only; no PA details
    Note

    Prior authorization not specified in index (titration packs listed)

    This index fragment does not specify prior authorization requirements; it lists drug names and titration packs only.

    • Index-only fragment; refer to drug pages for PA
    Note

    Index listing — no PA indicated

    This index segment is a listing only and does not state prior authorization requirements.

    • Index content; no PA rules
    Note

    Prior authorization not listed on index pages

    No prior authorization requirements are specified on these index pages; they are listings only.

    • Index-only; consult policy pages for PA
    Note

    Prior authorization not specified in index

    This index section does not contain prior authorization requirements; it lists drugs and references only.

    • Index entries only; no PA requirements present
    Step Therapy

    Step therapy for Invega Hafyera: trial of Sustenna or Trinza for new starts

    Step therapy for Invega Hafyera applies to new starts only and requires a trial of Invega Sustenna or Invega Trinza.

    • Step applies to new starts only
    • Required trial: Invega Sustenna OR Invega Trinza
    Step Therapy

    Step therapy for Zonisade: trial of generic zonisamide capsule for new starts

    Step therapy for Zonisade applies to new starts only and requires a trial of a generic zonisamide capsule.

    • Step applies to new starts only
    • Required trial: generic zonisamide capsule
    Note

    No step therapy rules in index content

    These index pages do not include any step therapy rules; they are listings used to locate policy details.

    • Index-only content; no step therapy rules present
    Note

    No step therapy requirements in index fragment

    No step therapy requirements appear in this index fragment; consult the individual drug policy pages for any step therapy rules.

    • Index-only fragment; no step therapy details
    Note

    No step therapy rules presented in these index pages

    The index pages do not present step therapy rules; they only list drug names and references.

    • Index-only; no step therapy rules presented
    Note

    No step therapy information present in this fragment

    No step therapy information is present in this index fragment.

    • Consult specific drug pages for step therapy
    Note

    No step therapy rules included in this index section

    No step therapy rules are included in this index section; use the drug policy pages for step therapy requirements.

    • Index-only content; no step therapy rules
    Note

    No step therapy rules present in this index section

    No step therapy rules are present in this index section.

    • Index-only; no step therapy information
    Note

    No step therapy rules in index fragment

    This index fragment does not include step therapy rules.

    Note

    No step therapy rules in this index fragment

    No step therapy rules are included in this index fragment.

    Note

    No step therapy rules included in this index fragment

    This index fragment does not contain step therapy rules.

    Note

    No step therapy rules appear in index entries

    No step therapy rules appear in the index entries; consult the individual drug pages for any step therapy requirements.

    Note

    Provider actions — index fragment (empty summary)

    This index fragment is a listing only and does not provide provider action guidance.

    Note

    Provider actions — index fragment (empty summary)

    This index fragment is an index listing and contains no provider authorization or documentation requirements.

    Note

    Provider actions — index fragment (empty summary)

    This index fragment does not present step therapy rules or provider actions.

    Note

    No step therapy rules (index fragment)

    No step therapy rules are present in this index fragment.

    Documentation Required

    Documentation: prior topical therapy required for Diclofenac

    Documentation of prior topical therapy (topical fluorouracil or topical imiquimod) is required when requesting prior authorization for Diclofenac Sodium GEL 3%.

    • Provide clinical documentation showing trial of topical fluorouracil OR topical imiquimod
    Documentation Required

    Documentation: record trials of two generics for antidepressants (continuation accepted)

    Clinical records must document trials of two generics from the specified antidepressant list for new starts; documentation of prior therapy is acceptable for continuation requests.

    • Document trials of two generics (see antidepressant list)
    • For continuation, provide evidence of prior therapy
    Documentation Required

    Documentation: record trials of two generic atypical antipsychotics

    Requests for Fanapt or its titration packs must include clinical documentation of trials of two oral generic formulary atypical antipsychotics from the listed agents, or evidence of prior therapy for continuation.

    • Document trials of two generics from asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
    • For continuation, provide evidence of prior therapy
    Documentation Required

    Documentation: trial of Sustenna or Trinza required for Invega Hafyera new starts

    For new Invega Hafyera starts, include documentation showing trial of Invega Sustenna or Invega Trinza; for continuation, provide evidence of prior therapy.

    • Document trial of Invega Sustenna OR Invega Trinza for new starts
    • For continuation, provide evidence of prior therapy
    Documentation Required

    Documentation: trial of listed laxatives required for Relistor

    Requests for Relistor must include documentation of a trial of one of the listed laxatives prior to approval.

    • Document trial of lubiprostone, Constulose, Enulose, Generlac, OR lactulose
    Documentation Required

    Documentation: trial of generic carbidopa/levodopa required for Rytary

    Documentation of a trial of a generic carbidopa/levodopa containing formulation is required for Rytary prior authorization requests; documentation of prior therapy is acceptable for continuation.

    • Provide clinical documentation of trial of a generic carbidopa/levodopa formulation
    • For continuation, supply evidence of prior therapy
    Documentation Required

    Documentation: trial of generic zonisamide capsule required for Zonisade new starts

    For new starts of Zonisade, provide documentation of a trial of a generic zonisamide capsule; for continuation, evidence of prior therapy is acceptable.

    • Document trial of generic zonisamide capsule for new starts
    • For continuation, provide evidence of prior therapy
    Note

    Index entries only — no documentation requirements here

    Index entries list drug names and section markers for locating policy content; these index fragments do not specify documentation or submission requirements.

    • Index-only content; no documentation instructions provided
    Note

    Index pages — no documentation or provider action requirements

    These index pages do not include documentation or provider action requirements; consult the individual drug policy pages for submission instructions.

    • Index-only; no documentation requirements
    Note

    Index points to policy pages — no submission instructions here

    Index listings point to where full policy content can be found but do not include documentation or submission requirements in these fragments.

    • Refer to the indicated drug pages for documentation requirements
    Note

    Index only — no documentation requirements

    This index fragment is an index only and does not contain documentation requirements.

    Note

    Index fragment — no documentation requirements

    Index listings in this fragment do not contain documentation requirements.

    Note

    Index pages — no documentation requirements

    These index pages do not include documentation requirements for provider submissions.

    Note

    Provider actions — index fragment (empty summary)

    This index fragment provides no provider action or documentation requirements.

    Denial Risk

    Denial risk: missing documentation for Diclofenac

    Failure to document the required prior topical therapy for Diclofenac Sodium GEL 3% may result in denial of the prior authorization request.

    • Denial risk: no documentation of trial of topical fluorouracil or topical imiquimod
    Denial Risk

    Denial risk: missing generic trials for antidepressants

    For listed antidepressant products, lack of documented trials of two generics from the specified list may lead to non-approval for new starts.

    • Denial risk: no record of two generic antidepressant trials for new starts
    Denial Risk

    Denial risk: missing atypical antipsychotic trials

    For Fanapt and related titration packs, absence of documentation showing trials of two oral generic formulary atypical antipsychotics from the specified list may lead to denial for new starts.

    • Denial risk: missing trials of two generic atypical antipsychotics
    Denial Risk

    Denial risk: missing Sustenna/Trinza trial for Invega Hafyera

    For Invega Hafyera new starts, failure to document a trial of Invega Sustenna or Invega Trinza may result in non-approval.

    • Denial risk: no trial of Invega Sustenna or Invega Trinza documented for new starts
    Denial Risk

    Denial risk: missing laxative trials for Relistor

    For Relistor, absence of documentation of a trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) may trigger denial.

    • Denial risk: no trial of listed laxatives documented
    Denial Risk

    Denial risk: missing carbidopa/levodopa trial for Rytary

    For Rytary, failure to document a trial of a generic carbidopa/levodopa formulation may lead to non-approval.

    • Denial risk: missing trial of generic carbidopa/levodopa
    Denial Risk

    Denial risk: missing zonisamide trial for Zonisade

    For Zonisade, lack of documentation showing a trial of a generic zonisamide capsule for new starts may result in denial.

    • Denial risk: no trial of generic zonisamide capsule documented for new starts
    Note

    Index-only — no authorization or denial criteria here

    These index fragments do not state authorization triggers or denial criteria themselves; consult the individual drug policy pages for those details.

    Note

    Index pages — no documentation or provider action requirements

    No documentation or provider action requirements are included in these index pages; providers should refer to the specific drug policy pages for instructions.

    Note

    Index — no documentation or submission requirements provided

    Index entries point to policy locations but do not contain documentation or submission requirements in these fragments.

    Note

    Index only — no documentation requirements provided

    This index listing does not include documentation requirements; consult each drug's policy page for required documentation.

    Note

    Index — no documentation requirements in this fragment

    This index fragment is an index only and does not contain provider authorization or documentation requirements.

    Note

    Index only — no documentation requirements

    This section is an index only and does not include documentation requirements for provider submissions.

    Note

    Index listing — no provider authorization or documentation requirements

    This fragment is an index listing and does not contain provider authorization or documentation requirements.

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Index lists Fanapt titration packs — no documentation guidance here

    Index listing of Fanapt Titration Pack A and B is provided without guidance on required documentation; consult the Fanapt policy page for submission requirements.

    • Index lists Fanapt Titration Pack A/B but provides no documentation guidance
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Atypical antipsychotics initial therapy — single top-level criterion:

    Atypical antipsychotic criterion: Trial of two oral generic formulary atypical antipsychotic agents from: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone. Approve for continuation of prior therapy.

    Formulary ID: 26216, Version: 11

    Antidepressants - Score; Atypical Antipsychotics - Score; Auvelity; Diclofenac Sodium
    Index entry
    DefinitionIndex entry: a reference line listing a drug name and the page or score location within the policy document.
    UsageUsed on index pages to direct readers to the detailed policy or score pages for a listed drug.
    Example format<Drug name> ........................................ <page number>, <Score label>
    Index of Drugs
    TermIndex of Drugs
    NotesShows grouped listings such as Emsam and Exxua with repeated index lines pointing to page 2 for detailed entries.
    ExamplesEmsam; Exxua; Exxua Titration Pack
    Exxua Titration Pack
    TermExxua Titration Pack
    Index referenceListed repeatedly on index pages showing cross-reference to page 2 for the Exxua titration pack entries.
    Associated itemsExxua (brand) appears alongside Exxua Titration Pack on index lines.
    Fanapt Titration Pack
    TermFanapt Titration Pack
    Index referenceAppears on index pages with cross-reference to page 3; associated with Fanapt brand and Titration Pack A (and B).
    Related entriesFanapt; Fanapt Titration Pack A; Fanapt Titration Pack B
    Exxua Titration Pack
    TermExxua Titration Pack
    Index patternRepeated lines on multiple index pages referencing Exxua Titration Pack pointing to page 2.
    NotesUsed as an index pointer only; the index does not contain titration or clinical instructions.
    Definitions
    Definitions sectionThis area contains index/table-of-contents entries (drug names and cross-references).
    ScopeIndex entries only — no clinical definitions or coverage criteria are provided on these pages.
    Typical line<Drug name> ........................................ <page number>, <optional score label>
    Fanapt Titration Pack A / B
    TermFanapt Titration Pack A / B
    Index locationListed on index pages with cross-reference to page 3; both Pack A and Pack B are referenced in the index.
    Associated brandFanapt